ATE450272T1 - Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene - Google Patents

Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene

Info

Publication number
ATE450272T1
ATE450272T1 AT04819666T AT04819666T ATE450272T1 AT E450272 T1 ATE450272 T1 AT E450272T1 AT 04819666 T AT04819666 T AT 04819666T AT 04819666 T AT04819666 T AT 04819666T AT E450272 T1 ATE450272 T1 AT E450272T1
Authority
AT
Austria
Prior art keywords
bordetella
cell responses
adenylate cyclase
responses against
cyclase toxin
Prior art date
Application number
AT04819666T
Other languages
English (en)
Inventor
Gilles Dadaglio
Claude Leclerc
Daniel Ladant
Den Eynde Benoit Van
Sandra Morel
Cecile Bauche
Original Assignee
Pasteur Institut
I N S E R M Inst Nat De La San
Ludwig Inst Cancer Res
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, I N S E R M Inst Nat De La San, Ludwig Inst Cancer Res, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE450272T1 publication Critical patent/ATE450272T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
    • F16C25/00—Bearings for exclusively rotary movement adjustable for wear or play
    • F16C25/06—Ball or roller bearings
    • F16C25/08—Ball or roller bearings self-adjusting
    • F16C25/083—Ball or roller bearings self-adjusting with resilient means acting axially on a race ring to preload the bearing
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
    • F16C27/00—Elastic or yielding bearings or bearing supports, for exclusively rotary movement
    • F16C27/06—Elastic or yielding bearings or bearing supports, for exclusively rotary movement by means of parts of rubber or like materials
    • F16C27/066—Ball or roller bearings
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
    • F16C33/00—Parts of bearings; Special methods for making bearings or parts thereof
    • F16C33/72—Sealings
    • F16C33/76—Sealings of ball or roller bearings
    • F16C33/78—Sealings of ball or roller bearings with a diaphragm, disc, or ring, with or without resilient members
    • F16C33/7886—Sealings of ball or roller bearings with a diaphragm, disc, or ring, with or without resilient members mounted outside the gap between the inner and outer races, e.g. sealing rings mounted to an end face or outer surface of a race
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16C—SHAFTS; FLEXIBLE SHAFTS; ELEMENTS OR CRANKSHAFT MECHANISMS; ROTARY BODIES OTHER THAN GEARING ELEMENTS; BEARINGS
    • F16C19/00—Bearings with rolling contact, for exclusively rotary movement
    • F16C19/02—Bearings with rolling contact, for exclusively rotary movement with bearing balls essentially of the same size in one or more circular rows
    • F16C19/04—Bearings with rolling contact, for exclusively rotary movement with bearing balls essentially of the same size in one or more circular rows for radial load mainly
    • F16C19/06—Bearings with rolling contact, for exclusively rotary movement with bearing balls essentially of the same size in one or more circular rows for radial load mainly with a single row or balls

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04819666T 2003-11-21 2004-11-19 Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene ATE450272T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52363203P 2003-11-21 2003-11-21
PCT/EP2004/014086 WO2005053738A1 (en) 2003-11-21 2004-11-19 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens

Publications (1)

Publication Number Publication Date
ATE450272T1 true ATE450272T1 (de) 2009-12-15

Family

ID=34652257

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04819666T ATE450272T1 (de) 2003-11-21 2004-11-19 Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene

Country Status (11)

Country Link
US (4) US20050271679A1 (de)
EP (2) EP2193804B1 (de)
JP (1) JP4976853B2 (de)
AT (1) ATE450272T1 (de)
CA (1) CA2546452C (de)
DE (1) DE602004024440D1 (de)
ES (1) ES2337694T3 (de)
HK (1) HK1093314A1 (de)
PL (1) PL1684801T3 (de)
PT (1) PT1684801E (de)
WO (1) WO2005053738A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331348T3 (es) 2000-09-15 2009-12-30 Pasteur Institut Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b.
WO2005053738A1 (en) 2003-11-21 2005-06-16 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
DK1576967T3 (da) * 2004-03-18 2008-01-21 Pasteur Institut Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse
EP1894941A1 (de) 2006-09-01 2008-03-05 Institut Pasteur Behandlung von Gebärmutterhalskarzinomen mit einer rekombinanten Adenylat-Cyclase die HPV-Antigene trägt
WO2008025848A2 (en) * 2006-09-01 2008-03-06 Bt Pharma Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells
WO2008121171A1 (en) * 2007-01-12 2008-10-09 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for antibacterial interventions
US9095578B2 (en) * 2007-01-12 2015-08-04 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
EP2478915A1 (de) 2011-01-24 2012-07-25 Genticel cyaA-getragene Polypeptid(e) und Verwendung zur Induzierung von therapeutischen und prophylaktischen Immunantworten
US9345755B2 (en) * 2012-02-20 2016-05-24 University Of Virginia Patent Foundation Composition and methods for treating melanoma
EP2690172A1 (de) 2012-07-23 2014-01-29 Genticel CYAA-basierte chimäre Proteine mit einem heterologen Polypeptid und deren Verwendungen bei der Induktion von Immunreaktionen
WO2017013421A1 (en) 2015-07-20 2017-01-26 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935580A (en) 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
EP1715047A3 (de) 1992-04-21 2008-08-27 Institut Pasteur Rekombinante Mutanten zur Induktion spezifischer Immunantworten
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
KR100922809B1 (ko) * 1999-05-06 2009-10-21 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
CN1402782A (zh) * 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage－a12抗原肽及其应用
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
ES2331348T3 (es) 2000-09-15 2009-12-30 Pasteur Institut Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b.
EP1489092A1 (de) * 2003-06-18 2004-12-22 Institut Pasteur Modifizierte Bordetella Adenylatcyclase mit oder ohne CD11b/CD18 Interaktionsdomäne und seine Verwendungen
WO2005053738A1 (en) 2003-11-21 2005-06-16 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens

Also Published As

Publication number Publication date
EP2193804B1 (de) 2015-12-23
PL1684801T3 (pl) 2010-07-30
JP4976853B2 (ja) 2012-07-18
US20050271679A1 (en) 2005-12-08
US20140227323A1 (en) 2014-08-14
US9410139B2 (en) 2016-08-09
US20100310594A1 (en) 2010-12-09
PT1684801E (pt) 2010-03-08
JP2007511233A (ja) 2007-05-10
DE602004024440D1 (de) 2010-01-14
EP1684801A1 (de) 2006-08-02
ES2337694T3 (es) 2010-04-28
HK1093314A1 (en) 2007-03-02
EP1684801B1 (de) 2009-12-02
US20090117143A1 (en) 2009-05-07
EP2193804A2 (de) 2010-06-09
CA2546452C (en) 2015-01-20
WO2005053738A1 (en) 2005-06-16
EP2193804A3 (de) 2010-06-30
CA2546452A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
HK1093314A1 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
DE69533295D1 (de) Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
NO994983L (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
NO20020255D0 (no) Fc-fusjonsproteiner for forsterkning av immunogenisiteten av protein og peptidantigener
TR199801722T2 (xx) Peptit imm�nojenler.
NO20011586D0 (no) Nye metoder for terapeutisk vaksinasjon
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
CY1114855T1 (el) Αντισωματα και μορια που προερχονται απο αυτα που δεσμευονται στις πρωτεϊνες toy steap-1
WO2008026071A3 (en) Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying hpv antigens
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
DK1328547T3 (da) Identifikation og modifikation af immundominante epitoper i polypeptider
DE69824013D1 (de) Impfstoff gegen hpv
ATE372784T1 (de) Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
ATE454159T1 (de) Von survivin abgeleitete peptide und deren verwendung
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
ATE402956T1 (de) Neue, mhc klasse ii assoziierte peptide
DE69131829D1 (de) Gp75 als tumorimpfstoff gegen melanome
TNSN08184A1 (en) Chimeric antigens and vaccines
DE3585370D1 (de) Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen.
FI854839A (fi) Vaccin eller diagnostisk produkt erhaollen fraon peptid, samt daeri anvaendbar polypeptid.
ATE525470T1 (de) Antigene epitope des faktors viii, inhibitoren dagegen, und deren verwendungen
ES2199047A1 (es) Metodo de diagnostico inmunologico de la dirofilariosis pulmonar humana

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1684801

Country of ref document: EP